Lobe Sciences raises $2.16 million for sickle cell drug development

Lobe Sciences Ltd. has completed a two-tranche non-brokered private placement of common shares, raising a total of $2,160,000. The first tranche, closed on August 19, 2026, raised $2,100,000, followed by a second tranche that raised $60,000.

The company issued a total of 25,411,762 shares at a price of $0.085 per share. Lobe Sciences intends to use the funds for working capital, general corporate purposes, and the advancement of its S-100 drug candidate for the treatment of sickle cell disease.

A portion of the proceeds will be allocated to its subsidiary, Applied Lipid Technologies, Inc., to support the S-100 program as it moves toward human clinical trials. The company confirmed it has already procured the active pharmaceutical ingredient necessary for these studies.